Natalizumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Alert Card
Physician Educational Material
Subsidy Information and Financing Scheme
No
Active ingredient: Natalizumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
01/07/2026 Disease-modifying therapies for treating multiple sclerosis (opens in new tab)
The Ministry of Health’s Drug Advisory Committee has recommended:
Cladribine 10 mg tablet for treating relapsing-remitting multiple sclerosis,
Fingolimod 0.25 mg and 0.5 mg capsules for treating relapsing-remitting multiple sclerosis, and
Siponimod 0.25 mg and 2 mg tablets for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
Funding status
[R] Cladribine 10 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.
[R] Fingolimod (Gilenya) 0.25 mg and 0.5 mg capsules are recommended for reclassification from the MAF to the Standard Drug List (SDL) from 1 September 2026.
[R] Siponimod 0.25 mg and 2 mg tablets are recommended for inclusion on the MAF for the abovementioned indication from 4 January 2022.
[NR] SDL subsidy and MAF assistance do not apply to any formulations or strengths of alemtuzumab, dimethyl fumarate, interferon beta-1a, natalizumab, ocrelizumab, ofatumumab or teriflunomide for treating adults or children with any form of multiple sclerosis.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals (opens in new tab) or Polyclinics (opens in new tab) for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tysabri Infusion, Solution Concentrate 300 mg/15 mL |
|